Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Pharmacy | Rheumatology | Anesthesiology & Pain | Journal

Back to Journal Articles

Sustained Response to Repeat Rituximab Seen in RA

Last Updated: August 23, 2010.

 

Similar effect from various doses, though highest dose may be slightly better

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Three rituximab dosing regimens have similar efficacy for rheumatoid arthritis that is no longer responding to methotrexate, and retreatment after 24 weeks results in a more sustained response through to 48 weeks, according to a study in the September issue of Rheumatology.

MONDAY, Aug. 23 (HealthDay News) -- Three rituximab (RTX) dosing regimens have similar efficacy for rheumatoid arthritis that is no longer responding to methotrexate, and retreatment after 24 weeks results in a more sustained response through to 48 weeks, according to a study in the September issue of Rheumatology.

Andrea Rubbert-Roth, M.D., of the University of Cologne in Germany, and colleagues conducted a randomized study of the efficacy and safety of three different regimens of RTX for active rheumatoid arthritis despite being on a stable methotrexate regimen. Patients were randomized to receive two doses of RTX at baseline and at 24 months in one of three groups: 2 × 500 mg and 2 × 500 mg; 2 × 500 mg and 2 × 1000 mg (dose escalation group); and 2 × 1000 mg and 2 × 1000 mg.

The researchers found no significant differences between the treatment groups in ACR20 response at Week 48. The 2 × 1000 mg regimen was associated with a higher proportion of patients who maintained or improved their Week 24 responses at Week 48. There was no significant improvement associated with dose escalation in the 2 × 500 mg to 2 × 1000 mg regimen compared to the 2 × 500 mg and 2 × 500 mg regimen. Safety was comparable across treatment groups.

"Although RTX doses and retreatment regimens could not be clearly differentiated, several efficacy outcomes favored treatment with RTX 2 × 1000 mg. Repeat treatment at Week 24 with RTX maintained the response achieved with the first course and may be associated with improved efficacy outcomes," the authors write.

F. Hoffmann-La Roche, Biogen Idec, and Genentech sponsored the study. Several authors disclosed financial relationships with medical device and/or pharmaceutical companies, including Roche.

Abstract
Full Text

Copyright © 2010 HealthDay. All rights reserved.


Previous: Adult Victims of Violence More Likely to Spank Children Next: Virus May Be Associated With Chronic Fatigue Syndrome

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.